Finding Support and Reward from Alzheimer’s Clinical Trials

Our 2020 Champion Award winner wrote an opinion piece on her reason for getting involved in Alzheimer’s clinical trials and how her trial was her saving grace during the COVID-19 pandemic. Ann Bellotti is a former clinical social worker and an Alzheimer’s clinical trial volunteer at the Alzheimer’s Disease and Memory Disorders Center (ADMDC) at […]

Read More…

A Different Type of Public Service: Clinical Trials

Citizen Scientist Nominee, Florida state Representative Matthew Willhite, writes about his mother’s experience with Alzheimer’s disease and GAP-Net site, JEM Research Institute. Before she was diagnosed with Alzheimer’s disease, my mom was a nurse for 30 years. Her compassion for others and her tireless strength inspired me to become a Navy corpsman, a firefighter, a […]

Read More…

Walk to End Alzheimer’s Represents a Sea of Personal Stories

GAP-Net site Cleveland Clinic is hosting the Cleveland Walk to End Alzheimer’s on October 4, 2020. Guest columnist Caroline James is the Business Development Specialist at Independence Village & StoryPoint Avon Lake and Retention Chair for the Cleveland Walk to End Alzheimer’s. I’ve worked in senior care for seven years, often helping those with dementia or Alzheimer’s […]

Read More…

Clinical Trial Practitioners Key to Jumpstarting Alzheimer’s Research Efforts

GAP President John Dwyer was featured in ACRP about what clinical trials need to be doing to increase awareness and hasten treatments. The clinical trial industry continues to grapple with finding new and more effective ways to expand its efforts to combat Alzheimer’s. The obstacles are real. Alzheimer’s trials cost more per patient than trials […]

Read More…

An Alzheimer’s Quest: Enrolling More Black People in Clinical Trials

GAP President, John Dwyer, was featured in a Wall Street Journal article on the importance of Black, African-American, Hispanic and Latinx communities being aware of and enrolling in Alzheimer’s clinical trials, and what GAP is doing to help. Brian Van Buren applied to five Alzheimer’s disease clinical trials after being diagnosed with mild cognitive impairment […]

Read More…

Local Columnist Surprised by Result of Memory Assessment

Below is a press release from GAP-Net site, Okanagan Clinical Trials, regarding a high profile member of the community completeing a memory assessment. Kelowna (July 21, 2020) – Maxine Dehart, local city councillor, hotelier and journalist, decided to book a memory assessment for herself after featuring Okanagan Clinical Trials as part of her Straight from DeHart column in May. […]

Read More…

Don’t Let COVID-19 Destroy Alzheimer’s Research

GAP President John Dwyer wrote a piece in The Hill urging Congress to ensure research centers involved in Alzheimer’s clinical trials will have access to COVID-19 relief funds. COVID-19 has had a devastating impact on clinical trials and the medical research infrastructure that scientists depend upon to develop new drugs for Alzheimer’s and all the diseases we fear most. Without action, […]

Read More…

Alzheimer’s Research Needs Your Help

Alice Bailey, a GAP Citizen Scientist Award nominee, wrote an Op-Ed piece in the Cambridge Chronicle about her experience as an Alzheimer’s patient and clinical trial volunteer. For many seniors, Alzheimer’s disease is surrounded by fear. Fear of the diagnosis can be so strong that some don’t want to learn about or talk about the […]

Read More…

Alzheimer’s Researchers Fight Delays Caused by COVID-19

GAP President John Dwyer and GAP-Net Site Roper St. Francis Healthcare Research and Innovation Center in Charleston, South Carolina were featured on LIVE 5 WCSC News about the need for Alzheimer’s clinical trials to begin again. CHARLESTON, S.C. (WCSC) – Medical experts are worried that the COVID-19 pandemic has put delays on the search for […]

Read More…

In the Wake of COVID-19: Trials Interrupted, Delayed, Cancelled

GAP President John Dwyer was quoted in AlzForum about the challenges and changes in Alzheimer’s clinical trials due to COVID-19. As Alzheimer’s research comes to, scientists are taking stock of the damage. In the academic world, the main cost was time (see Part 1 of this story). For most clinical studies, the damage was more tangible, with […]

Read More…